Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.
Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.
Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264
VanderWalde NA, Meyer AM, Deal AM, Layton JB, Liu H, Carpenter WR, Weissler MC, Hayes DN, Fleming ME, Chera BS. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):30-7. doi: 10.1016/j.ijrobp.2014.01.053